Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021
8
2021
Highlights
Purpose and sustainability (ESG)
Adding value to society:
- Medical treatment provided to 34.6 million people living with diabetes in 2021
- 46 new vulnerability assessments conducted enabling access to insulin to
around 82,000 people living with diabetes
- Reaching 18 countries and around 32,000 children in Changing Diabetes®
in Children
Progress towards zero environmental impact:
- 43% reduction in CO2 emissions compared to 2019
Evolve culture and ensure distinct core capabilities:
Launch of an aspirational gender diversity target
Strategic
Aspirations 2025
- Being respected for adding value to society
- Progress towards zero environmental impact
- Ensure distinct core capabilities and evolve culture
Innovation and therapeutic focus
Further raise innovation bar for diabetes treatment:
Approval of XulthophyⓇ and Ozempic® in China for the treatment
of type 2 diabetes
- Resubmission of semaglutide 2.0 mg in the US and approval
in the EU in January 2022
- Phase 1 trial completed with a glucose-sensitive insulin
Develop superior treatment solutions for obesity:
Approval of Wegovy, semaglutide 2.4 mg, in the US and approval in
the EU in January 2022
Phase 3a development initiated with 50 mg oral semaglutide in obesity
Commercial execution
Strengthen diabetes leadership to more than one-third:
- Diabetes value market share increased by 0.8 percentage point
to 30.1% (MAT)
Strengthen and progress Biopharm pipeline:
- Sogroya® phase 3 programme in children with growth
hormone deficiency successfully completed
First Mim8 phase 1/2 trial cohorts successfully completed
Establish presence in other serious chronic diseases:
Phase 3a development initiated with ziltivekimab in cardiovascular
disease and semaglutide in NASH and Alzheimer's disease
Acquisition of Dicerna Pharmaceuticals and its RNAi platform
to be applied across therapy areas
Strengthen obesity leadership and double sales:
Obesity care sales increased by 55% (CER) to DKK 8.4 billion
Secure a sustained growth outlook for Biopharm:
- Biopharm sales increased by 4% (CER) to DKK 19.2 billion
- Further raise the innovation bar for diabetes treatment
- Develop a leading portfolio of superior treatment solutions
for obesity
- Strengthen and progress the Biopharm pipeline
- Establish presence in other serious chronic diseases focusing
on cardiovascular disease (CVD), NASH and chronic kidney
disease (CKD)
- Strengthen diabetes leadership - aim at global value market
share of more than 1/3
- Strengthen obesity leadership and double 2019 reported sales
- Secure a sustained growth outlook for Biopharm
Financials
Deliver solid sales and operating profit growth:
- Sales growth at 14% (CER)
- International Operations sales growth of 14% (CER)
- US sales growth of 13% (CER) with 60% of sales coming
-
from products launched since 2015
Operating profit growth of 13% (CER)
Drive operational efficiencies:
- Continued productivity gains in Product Supply
Enable attractive capital allocation to shareholders:
Free cash flow of DKK 29.3 billion
- Share buyback of DKK 20 billion
- Total dividend of DKK 10.40 per share and payout ratio of 49.6%
- Deliver solid sales and operating profit growth:
- Deliver 6-10% sales growth in IO
- Transform 70% of sales in the US (from 2015 to 2022)
- Drive operational efficiencies across the value chain to enable
investments in future growth assets
- Deliver free cash flow to enable attractive capital allocation to
shareholdersView entire presentation